KCNAB1 encodes the potassium voltage-gated channel subfamily A regulatory beta subunit 1, which serves as an auxiliary subunit that modulates voltage-gated potassium channels. The protein exhibits regulatory activity on potassium channel complexes and demonstrates NADPH binding and alcohol dehydrogenase activity 12. KCNAB1 functions by assembling with various Kv channels (such as Kv1.3 and Kv1.5) to modify their electrophysiological properties, including induction of fast and incomplete inactivation patterns, with trafficking regulated through PKC-dependent phosphorylation mechanisms 2. The gene shows significant disease relevance across multiple conditions. Genetic variants in KCNAB1, particularly rs6770663, are associated with bevacizumab-induced hypertension in cancer patients, with validation across multiple independent cohorts 34. Additionally, KCNAB1 variants show association with lateral temporal epilepsy, supporting its role as a susceptibility factor 5, and with age-related nuclear cataract in Asian populations 6. Clinically, KCNAB1 expression is altered in various pathological states, including overexpression in schizophrenia patients' lymphocytes 1 and dysregulation in sudden cardiac death cases 7. The rs6770663 variant demonstrates particular clinical utility as a predictive biomarker for bevacizumab-induced hypertension when combined with plasma protein levels 4.